Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cardiff LexingtonCDIX +0.79%27 Days Sales Outstanding is 923.22 as of Mar. 2026, which is 1414% above its 10-year median of 60.96. GuruFocus rates CDIX with a GF Score™ of 27/100 and a GF Value™ of $0.08 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 657 Healthcare Providers & Services companies, Cardiff Lexington ranks worse than 99.39% on this metric.
The historical rank and industry rank for Cardiff Lexington's Days Sales Outstanding or its related term are showing as below:
CDIX'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 6.13 Med: 60.96 Max: 689.18
Current: 689.18
During the past 13 years, Cardiff Lexington's highest Days Sales Outstanding was 689.18. The lowest was 6.13. And the median was 60.96.
CDIX's Days Sales Outstanding is ranked worse than 99.39% of 657
companies
in the Healthcare Providers & Services industry
Industry Median: 45.73
vs CDIX: 689.18
Cardiff Lexington's Days Sales Outstanding
increased
from Mar. 2025 (523.15) to Mar. 2026 (923.22).
Cardiff Lexington (OTCPK:CDIX) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Cardiff Lexington Days Sales Outstanding Related Terms
Cardiff Lexington Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Cardiff Lexington's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CDIX vs AMS, SYRA, BMGL: Days Sales Outstanding Comparison
For the Medical Care Facilities subindustry, Cardiff Lexington's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cardiff Lexington Days Sales Outstanding vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Cardiff Lexington's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Cardiff Lexington's Days Sales Outstanding falls into.
Cardiff Lexington Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Days Sales Outstanding of 923.22 mean?
Cardiff Lexington (CDIX) has a Days Sales Outstanding of 923.22 as of Mar. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Cardiff Lexington and its competitors. This is 1414% above median its historical median of 60.96. Over the past decade, Cardiff Lexington's Days Sales Outstanding has ranged from 6.13 to 689.18. According to the industry distribution chart, Cardiff Lexington ranks #653 out of 657 companies in the Healthcare Providers & Services industry, placing it in the top 99.4%.
Is Cardiff Lexington's Days Sales Outstanding too high?
Cardiff Lexington's current Days Sales Outstanding of 923.22 is 1414% above median its 10-year median of 60.96. Over the past 10 years, this metric has ranged from a low of 6.13 to a high of 689.18. The Healthcare Providers & Services industry median Days Sales Outstanding is 45.73. Cardiff Lexington's value of 923.22 is 1918.8% above this industry median. Based on the distribution chart, Cardiff Lexington ranks #653 out of 657 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Cardiff Lexington has a GF Score™ of 27/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cardiff Lexington's Days Sales Outstanding compare to AMS and SYRA?
According to the Healthcare Providers & Services industry distribution chart, Cardiff Lexington ranks #653 out of 657 companies for Days Sales Outstanding. This places Cardiff Lexington in the lower half of its industry. The industry median Days Sales Outstanding is 45.73. Cardiff Lexington's value of 923.22 is 1918.8% above this benchmark. Historically, Cardiff Lexington's own Days Sales Outstanding has ranged from 6.13 to 689.18 over the past decade. While the company's 10-year median is 60.96 vs. the industry median of 45.73, Cardiff Lexington has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Healthcare Providers & Services company?
The median Days Sales Outstanding among Healthcare Providers & Services companies is 45.73, based on 657 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cardiff Lexington's current Days Sales Outstanding of 923.22 is 1918.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Cardiff Lexington and its competitors. For the Healthcare Providers & Services industry, the median Days Sales Outstanding is 45.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cardiff Lexington's current Days Sales Outstanding is 923.22, which is 1414% above median its own 10-year median of 60.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiff Lexington stock overvalued right now?
Based on GuruFocus' analysis, Cardiff Lexington (CDIX) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.08, compared to a current price of $0.51 — trading 537.5% above its estimated fair value. The current Days Sales Outstanding is 923.22, which is 1414% above median its 10-year median of 60.96 and 1918.8% above the Healthcare Providers & Services industry median of 45.73. Cardiff Lexington's overall GF Score™ is 27/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Cardiff Lexington (CDIX), the current Days Sales Outstanding is 923.22 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cardiff Lexington (CDIX) Overvalued in 2026?
Based on GuruFocus' analysis, Cardiff Lexington stock appears to be overvalued.
The current stock price of $0.51 is trading 537.5% above its estimated GF Value™ of $0.08.
GuruFocus considers Cardiff Lexington to be Significantly Overvalued.
Key valuation signals for CDIX:
Days Sales Outstanding: 923.22 (1414% above median its 10-year median of 60.96)
GF Value™: $0.08 vs. price of $0.51 (537.5% above fair value)
Industry Position: 1918.8% above the Healthcare Providers & Services median (#653 of 657)
No single metric tells the full story. See the CDIX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cardiff Lexington Corp is an acquisition holding company, conducting its operations through its operating subsidiaries. The company has two reportable operating segments; Healthcare (Nova), and Real Estate (Edge View). The Healthcare segment generates all of the company's revenue and provides a full range of diagnostic and surgical services for injuries and disorders of the skeletal system and associated bones, joints, tendons, muscles, ligaments, and nerves. The Real estate segment consists of Edge View, a real estate company that owns various acres zoned medium-density residential.
27GF Score
Get the complete analysis for CDIX
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CDIX has been successfully added to your 
